Prevention of new-onset diabetes in patients with heart failure;Prevención de la diabetes mellitus en los pacientes con insuficiencia cardiaca

Revista Espanola de Cardiologia Suplementos

Volumn 6, Issue C, 2006, Pages

  Barrios Alonso, Vivencio ^a   Calderón, Alberto ^a   Escobar, Carlos ^a   Blanco, Blanca ^a   Asín, Enrique ^a  

^a HOSPITAL RAMÓN Y CAJAL   (Spain)

Author keywords

Angiotensin receptor blockers; Candesartan; Diabetes mellitus; Heart failure

Indexed keywords

AMLODIPINE; ATENOLOL; ATORVASTATIN; CANDESARTAN; DILTIAZEM; FELODIPINE; HYDROCHLOROTHIAZIDE; RAMIPRIL; SIMVASTATIN; TELMISARTAN; TRANDOLAPRIL; VALSARTAN; VERAPAMIL;

ARTICLE; CARDIOVASCULAR RISK; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DIABETES MELLITUS; HEART FAILURE; HUMAN; INCIDENCE; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM;

EID: 34848893366     PISSN: 11313587     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (61)

1. Medrano MJ, Cerrato E, Boix R, Delgado-Rodríguez M. Factores de riesgo cardiovascular en la población española: metaanálisis de estudios transversales. Med Clin (Barc). 2005;124:606-12.
2. American Diabetes Association. Position Statement: Standards of Medical Care in Diabetes. Diabetes Care. 2005;28:S4-36.
3. Barrios V, Campuzano R, Guzmán G. Diabetes y corazón. Hipertensión. 2002;19:28-39.
4. Laakso M. Hyperglycemia and cardiovascular disease in type 2 diabetes. Diabetes. 1999;48:937-42.
5. Neil A, Hawkins M, Potok M, Thorogood M, Cohen DA, Mann J. A prospective population-based study of microalbuminuria as a predictor of mortality in NIDDM. Diabetes Care. 1993;16:996-1003.
6. Barrios V. Enfermedad cardiovascular y diabetes. En: Alpízar M, editor. Guía para el manejo integral del paciente diabético. México DF: Manual Moderno; 2001. p. 83-104.
7. Gu K, Cowie CC, Harris MI. Diabetes and decline in heart disease mortality in US adults. JAMA. 1999;281:1291-7.
8. Kannel WB, Hjortland M, Castelli WP. Role of diabetes in congestive heart failure. The Framingham Study. Am J Cardiol. 1974;34:29-34.
9. Ingelsson E, Sundström J, Ärnlöv J, Zetheluis B, Lind L. Insulin resistance and risk of congestive heart failure. JAMA. 2005;294:334-41.
10. González-Juanatey JR, Alegría E, García Acuña JM, González I, Lozano JV. Impacto de la diabetes en las enfermedades cardiacas en España. Estudio CARDIOTENS 1999. Med Clin (Barc). 2001;116:686-91.
11. Barrios V, Peña G, González-Juanatey JR, Alegría E, Lozano JV, Llisterri JL, et al. Hipertensión arterial e insuficiencia cardiaca en las consultas de atención primaria y de cardiología en España. Rev Clin Esp. 2003;203:334-42.
12. Duggirala MK, Cuddihy RM, Cuddihy MT, Naessens JM, Cha SS, Mandrekar JN, et al. Predictors of blood pressure control in patients with diabetes and hypertension seen in primary care clinics. Am J Hypertens. 2005;18:833-8.
13. Álvarez-Sala LS, Suárez C, Mantilla T, Franch J, Ruilope LM, Banegas JR, et al. Estudio PREVENCAT: Control del riesgo cardiovascular en Atención Primaria. Med Clin (Barc). 2005;124:406-10.
14. Barrios V, Tomás JP, Navarro A, Esteras A, Luque M, Romero J, et al. Efectividad antihipertensiva y tolerabilidad de lercanidipino en diabéticos, en pacientes con hipertensión sistólica aislada y en ancianos. Análisis de subgrupos del estudio ELYPSE. Hipertensión. 2003;20:347-53.
15. Flather MD, Yusuf S, Kober L, Pfeffer MA, Hall A, Murray G, et al. Lomg-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. ACE-Inhibitor Myocardial Infarction Collaborative Group. Lancet. 2000;355:1575-81.
16. Eguchi K, Kario K, Hoshide S, Ishikawa J, Morinari M, Shimada K. Type 2 diabetes is associated with left ventricular concentric remodelling in hypertensive patients. AM J Hypertens. 2005;7:221-8.
17. Aguilar D, Salomon SD, Kober L, Rouleau JL, Skali H, Mc Murray JJ, et al. Newly diagnosed and previously known diabetes mellitus and 1-year outcomes of acute myocardial infarction: the Valsartan in acute myocardial infarction (VALIANT) Trial. Circulation. 2004;110:1572-8.
18. Verdecchia P, Reboldi G, Angeli F, Borgioni C, Gattobigio R, Filippucci L, et al. Adverse prognostic significance of new diabetes in treated hypertensive subjects. Hypertension. 2004;43:963-9.
19. Lindholm LH, Ibsen H, Borch-Johnsen K, Olsen MH, Wachtell K, Dahlof B, et al. Risk of new-onset diabetes in the Losartan Intervention For Endpoint reduction in hypertension study. J Hypertens. 2002;20:1879-86.
20. Abuissa H, Bell DSH, O'Keefe Jr JH. Strategies to prevent type 2 diabetes. Curr Med Res Opin. 2005;21:1107-14.
21. Barrios V, Ruilope LM. Hypertension with left ventricular hypertrophy/ diastolic dysfunction. En: Sleight P, Bakris G, Mancia G, Messerli F, Opie L, editors. Clinical cases in hypertension. Specific treatment strategies (Volume two). Richmond upon Thames (Reino Unido): PAN Communications; 2000. p. 16-22.
22. Messerli FH, Grossman E, Leonetti G. Antihypertensive therapy and new onset diabetes. J Hypertens. 2004;22:1845-7.
23. Bristow MR, Gilbert EM, Abraham WT, Adams KF, Fowler MB, Hershberger RE, et al. Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. Circulation. 1996;94:2807-16.
24. Gress TW, Nieto FJ, Shahar E, Wofford MR, Brancati FL. Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. Atherosclerosis Risk In Communities (ARIC) study. N Engl J Med. 2000;342:905-12.
25. Ruilope LM, Barrios V. Pharmacologic treatment. Section 3: CK Francis, GYJ Lip. Hypertensive Heart Disease. En: Crawford MH, DiMarco JP, editors. Cardiology. Londres: Mosby; 2001; p. 8.1-8.8.
26. Bakris GL, Fonseca V, Katholi RE, McGill JB, Messerli FH, Phillips RA, et al; for the GEMINI Investigators. Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized contyrolled trial. JAMA. 2004;292:2227-36.
27. Poole-Wilson PA, Swedberg K, Cleland JGF, Di Lenarda A, Hanrath P, Komajda M, et al; for the COMET Investigators. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomized controlled trial. Lancet. 2003;362:7-13.
28. Mancia G, Brown M, Castaigne A, De Leeuw P, Palmer CR, Rosenthal T, et al. Outcomes with nifedipine GITS or co-amilozide in hypertensive diabetics and nondiabetics in intervention as a goal in hypertension (INSIGHT). Hypertension. 2003;41:431-6.
29. Hansson L, Hedner T, Lund-Johansen P, Kjeldsen SE, Lindholm LH, Syvertsen JO, et al. Randomised trial of effects of calcium antagonists compared with diuretics and beta-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study. Lancet. 2000;356:359-65.
30. Pepine CJ, Handberg EM, Cooper-DeHoff RM, Marks RG, Kowey P, Messerli FH, et al; for the INVEST Investigators. A calcium antagonist versus a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA. 2003;290:2805-16.
31. Hansson L, Lindholm LH, Ekbom T, Dahlöf B, Lanke J, Scherstén B, et al; for the STOP-Hypertension-2 study group. Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity in the Swedish Trial in Old Patients with Hypertension-2 study. Lancet. 1999;354: 1751-6.
32. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker versus diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002;288:2981-97.
33. Barrios V, Ortega J. ACE inhibitors in the treatment of heart failure [letter]. Heart Failure. 1999;7:2-5.
34. Shindler DM, Kostis JF, Yusuf S, for the SOLVD Investigators. Diabetes mellitus, a predictor of morbidity and mortality in the studies of left ventricular dysfunction trials and registry. Am J Cardiol. 1996;77:1017-20.
35. The Heart Outcomes Prevention Evaluation (HOPE) Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus. Results of the HOPE and micro-HOPE study. Lancet. 2000;355:253-9.
36. Hansson L, Lindholm LH, Niskanen L, Lanke J, Hedner T, Niklason A, et al. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet. 1999;353:611-6.
37. Yusuf S, Gerstein H, Hoogwerf B, Pogue J, Bosch J, Wolffebnbuttel BH, et al; for the HOPE Investigators. Ramipril and the development of diabetes. JAMA. 2001;286:1882-5.
38. The PEACE Trial Investigators. Angiotensin converting-enzyme inhibition in stable coronary artery disease. New Engl J Med. 2004;351:2058-68.
39. Wing LM, Reid CM, Ryan P, Beilin LJ, Brown MA, Jennings GL, et al; for the Second Australian National Blood Pressure Study Group. A comparison of outcomes with angiotensin-converting-enzyme inhibitors and diuretics for hypertension in the elderly. N Engl J Med. 2003;348:583-92.
40. Barrios V, Tomás JP, Calderón A, Escobar C. Papel de los ARA-II en el tratamiento de la hipertensión arterial. De la evidencia a la práctica clínica. Clin Invest Arterioscl. 2005;17:S70-82.
41. Barrios V, Campuzano R. Utilidad de los ARA-II en la insuficiencia cardiaca. Rev Clin Esp. 2003;203:28-32.
42. Ruilope LM, Barrios V, Volpe M. Renal implications of the reninangiotensin-aldosterone system blockade in heart failure. J Hypertens. 2000;18:1545-61.
43. Dahlof B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, De Faire U, et al; for the LIFE Study Group. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002;359:995-1003.
44. Lindholm LH, Persson M, Alaupovic P, Carlberg B, Svensson A, Samuelsson O. Metabolic outcome during 1 year in newly detected hypertensives: results of the Antihypertensive Treatment and Lipid Profile in a North of Sweden Efficacy Evaluation (ALPINE study). J Hypertens. 2003;21:1563-74.
45. Lithell H, Hansson L, Skoog I, Elmfeldt D, Hofman A, Olofsson B, et al. The study on cognition and prognosis in the elderly (SCOPE): principal results of a randomized double-blind intervention trial. J Hypertens. 2003;21:875-86.
46. Lithell H, Hansson L, Skoog I, Elmfeldt D, Hofman A, Olofsson B, et al. The study on cognition and prognosis in the elderly (SCOPE); outcomes in patients not receiving add-on therapy after randomization. J Hypertens. 2004;22:1605-12.
47. Kjeldsen SE, Julius S, Brunner H, Hansson L, Henis M, Ekman S, et al. Characteristics of 15,314 hypertensive patients at high coronary risk. The VALUE trial. The Valsartan Antihypertensive Long-term Use Evaluation. Blood Press. 2001;10:83-91.
48. Julius S, Kjeldsen SE, Weber M, Brunner HR, Ekman S, Hansson L, et al; for the VALUE trial group. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet. 2004;363:2022-31.
49. Yusuf S, Ostergren JB, Gerstein HC, Pfeffer MA, Swedberg K, Granger CB, et al; on behalf of the Candesartan in Heart Failure-Assessment of Reduction in Mortality and Morbidity Program (CHARM) Investigators. Effects of candesartan on the development of a new diagnosis of diabetes mellitus in patients with heart failure. Circulation. 2005;112:48-53.
50. McMurray JJ, Ostegren J, Swedberg K, Granberg CB, Held P, Michelson El, et al, CHARM Investigators and Committes. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet. 2003;362:767-71.
51. Granger CB, McMurray JJ, Yusuf S, Held P, Michelson EL, Olofsson B, et al; CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting enzyme inhibitors: the CHARM-Alternative trial. Lancet. 2003; 362: 772-76.
52. Yusuf S, Pfeffer MA, Swedberg K, Granger CB, Hled P, McMurray JJ, et al; CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet. 2003;362:777-81.
53. Opie L, Schall R. Old antihypertensives and new diabetes. J Hypertens. 2004;22:1453-8.
54. Sharma AM, Janke J, Gorzelniak K, Engeli S, Luft FC. Angiotensin blockade prevents type 2 diabetes by formation of fat cells. Hypertension. 2002;40:609-11.
55. Carlsson PO, Berne C, Jansson L. Angiotensin and endocrine pancreas: effect on islet blood flow and insulin secretion in rats. Diabetologia. 1998;41:127-33.
56. Gillespie EL, White CM, Kardas M, Lindberg M, Coleman C. The impact of ACE inhibitors or Angiotensin II type 1 receptor blockers on the development of new-onset type 2 diabetes. Diabetes Care. 2005;28:2261-6.
57. The Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346:393-403.
58. Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. JAMA. 2003;290:486-94.
59. Buchanan TA, Xiang AH, Peters RK, Kjos SL, Marroquin A, Goico J, et al. Preservation of pancreatio beta cell function and prevention of type 2 diabetes by pharmacological treatment of insulin-resistance in high-risk Hispanic women. Diabetes. 2002; 51: 2796-803.
60. Padwal R, Majumdar SR, Johnson JA, Varney J, McAlister FA. A systematic review of drug therapy or prevent type 2 diabetes. Diabetes Care. 2005;28:736-44.
61. Kjekshus J, Dunselman P, Blideskog M, Eskilson C, Hjalmarson A, Mc Murray JV, et al; on behalf of the CORONA Study Group. A statin in the treatment of heart failure? Controlled rosuvastatin multinational study in heart failure (CORONA): Study design and baseline characteristics. Eur J Heart Fail. 2005;7:1059-69.